Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scynexis names new CEO

This article was originally published in Scrip

Executive Summary

Drug discovery and development company Scynexis has appointed Dr Marco Taglietti CEO, effective from 1 April 2015. Dr Taglietti, a member of Scynexis' board of directors, will succeed Dr Yves Ribeill in the position. Dr Ribeill will remain the company's president and will continue to serve on the company's board. In an unrelated matter Scynexis said Dr Carole Sable, the company's current chief medical officer, is stepping down effective 20 February 2015.

You may also be interested in...



BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco

Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC027823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel